Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Oct 30.

Published in final edited form as: Biol Blood Marrow Transplant. 2016 Jan 28;22(5):869–878. doi: 10.1016/j.bbmt.2015.12.030

Figure 2. — (A) Cytotoxicity and IFN-γ ELISPOTs directed at RPMI 8226, Daudi, and K562 targets after BATs infusions (Upper) and after SCT (Lower) in 12 patients. (B) (Left and Middle) IFN-γ ELISPOTs in patients who received BATs + SCT compared with patients who received SCT only (control group). (Right) The fold increase in IFN-γ ELISPOTs against RPMI 8226 at 6 to 12 months post-SCT in patients who remained in remission (uCR) compared with patients who relapsed (REL). (C) Data for 4 patients who received a single “booster” infusion of BATs at 6 to 15 months post-SCT. Booster infusion of BATs induced increases in IFN-γ ELISPOT responses when stimulated with MM-specific targets (RPMI 8226) and NK targets (K562) in all 4 patients at 2 and 4 weeks after booster BATs infusions.

Figure 2. — (A) Cytotoxicity and IFN-γ ELISPOTs directed at RPMI 8226, Daudi, and K562 targets after BATs infusions (Upper) and after SCT (Lower) in 12 patients. (B) (Left and Middle) IFN-γ ELISPOTs in patients who received BATs + SCT compared with patients who received SCT only (control group). (Right) The fold increase in IFN-γ ELISPOTs against RPMI 8226 at 6 to 12 months post-SCT in patients who remained in remission (uCR) compared with patients who relapsed (REL). (C) Data for 4 patients who received a single “booster” infusion of BATs at 6 to 15 months post-SCT. Booster infusion of BATs induced increases in IFN-γ ELISPOT responses when stimulated with MM-specific targets (RPMI 8226) and NK targets (K562) in all 4 patients at 2 and 4 weeks after booster BATs infusions.